Clinical Trials Directory

Trials / Recruiting

RecruitingNCT02370199

Peripheral Blood Flow Responses to Electromagnetic Energy

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
University of Alabama at Birmingham · Academic / Other
Sex
All
Age
18 Years – 59 Years
Healthy volunteers
Accepted

Summary

This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.

Detailed description

670 nm energy in the form of red light dilates isolated blood vessels. This study seeks to measure vessel dilation in human subjects exposed to this energy at different irradiance intensities (25 milliwatts (mW)/cm2 and 75 mW/cm2). The intent of this protocol is to measure blood flow in the gastrocnemius muscle before and after exposure to 670 nm light energy. This protocol will be performed in healthy subjects, who do not meet exclusion criteria. The study consists of one visit. Blood flow measurement will be performed using contrast enhanced ultrasound, a method by which ultrasound contrast is continuously infused into the blood stream. Ultrasound records images in the area of interest and flow is related to the intensity of the contrast in each image. After baseline blood flow images are collected, the subject will receive red light energy to the gastrocnemius muscle with concurrent blood flow measurements with contrast ultrasound. The subject will be monitored post procedure and the study will then be completed.

Conditions

Interventions

TypeNameDescription
DEVICE670 nm light670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
DRUGoctafluropropaneOctofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.

Timeline

Start date
2014-11-01
Primary completion
2027-12-31
Completion
2027-12-31
First posted
2015-02-24
Last updated
2025-04-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02370199. Inclusion in this directory is not an endorsement.